Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20402670 | 0.78 | POLB (0.33) | POLB | |
| SCHEMBL14349893 | 0.78 | POLB (0.33) | POLB | |
| SCHEMBL6057228 | 0.74 | CHRM2 (0.38) | POLB | |
| SCHEMBL3280098 | 0.74 | POLB (0.50) | POLBMEN1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL6057362 | 0.74 | ALDH1A1 (0.33) | POLB | |
| SCHEMBL8570280 | 0.74 | POLB (0.34) | POLBMEN1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL11494878 | 0.74 | MEN1 (0.33) | POLBMEN1KMT2A | |
| SCHEMBL20126490 | 0.74 | POLB (0.34) | POLBMEN1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL14905848 | 0.74 | POLB (0.31) | POLB | |
| SCHEMBL107675 | 0.74 | RIPK1 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230242486-A1 | PYRIDINYL MORPHOLINE COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY (CN) | 2023-08-03 | — | — | US | disclosed |
| US-11319410-B2 | Precursor for polyimide and use thereof | ETERNAL MATERIALS CO., LTD. (TW) | 2022-05-03 | — | — | US | disclosed |
| CN-114253069-A | Photosensitive resin composition, pattern forming method, cured film forming method, interlayer insulating film, and surface protective film | 信越化学工业株式会社 | 2022-03-29 | — | — | CN | disclosed |
| US-11198792-B2 | Method for preparing patterned coverlay on substrate | ETERNAL MATERIALS CO., LTD. (TW) | 2021-12-14 | — | — | US | disclosed |
| US-10731004-B2 | Polyimide precursor composition and use thereof | ETERNAL MATERIALS CO., LTD. (TW) | 2020-08-04 | — | — | US | disclosed |
| US-10696793-B2 | Process for preparing polyimides | ETERNAL MATERIALS CO., LTD. (TW) | 2020-06-30 | — | — | US | disclosed |
| US-10626220-B2 | Precursor for polyimide and use thereof | ETERNAL MATERIALS CO., LTD. (TW) | 2020-04-21 | — | — | US | disclosed |
| US-20200055986-A1 | PROCESS FOR PREPARING POLYIMIDES | ETERNAL MATERIALS CO., LTD. (TW) | 2020-02-20 | — | — | US | disclosed |
| US-10550073-B2 | Benzamide derivative | CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) | 2020-02-04 | — | — | US | disclosed |
| US-20180194899-A1 | PRECURSOR FOR POLYIMIDE AND USE THEREOF | ETERNAL MATERIALS CO., LTD. (TW) | 2018-07-12 | — | — | US | disclosed |
| US-20180148544-A1 | PRECURSOR FOR POLYIMIDE AND USE THEREOF | ETERNAL MATERIAL CO., LTD. (TW) | 2018-05-31 | — | — | US | disclosed |
| US-20180148544-A1 | PRECURSOR FOR POLYIMIDE AND USE THEREOF | ETERNAL MATERIAL CO., LTD. (TW) | 2018-05-31 | — | — | US | disclosed |
| US-20180148541-A1 | POLYIMIDE PRECURSOR COMPOSITION AND USE THEREOF | ETERNAL MATERIALS CO., LTD. (TW) | 2018-05-31 | — | — | US | disclosed |
| US-20180002567-A1 | POLYIMIDE DRY FILM AND APPLICATION THEREOF | ETERNAL MATERIALS CO., LTD. (TW) | 2018-01-04 | — | — | US | disclosed |
| EP-2346883-B1 | SELF DELIVERING BIO-LABILE PHOSPHATE PROTECTED PRO-OLIGOS FOR OLIGONUCLEOTIDE BASED THERAPEUTICS AND MEDIATING RNA INTERFERENCE | PETERSEN SCOTT G (US) | 2016-03-23 | — | — | EP | disclosed |
| US-8895744-B2 | Alfa-carboline inhibitors of NPM-ALK, RET, and Bcr-Abl | UNIVERSITA' DEGLI STUDI DI MILANO-BICOCCA (IT) | 2014-11-25 | — | — | US | disclosed |
| US-8895744-B2 | Alfa-carboline inhibitors of NPM-ALK, RET, and Bcr-Abl | UNIVERSITA' DEGLI STUDI DI MILANO-BICOCCA (IT) | 2014-11-25 | — | — | US | disclosed |
| US-20110281862-A1 | ALFA-CARBOLINE INHIBITORS OF NPM-ALK, RET, AND BCR-ABL | UNIVERSITA' DEGLI STUDI DI MILANO - BICOCCA (IT) | 2011-11-17 | — | — | US | disclosed |
| US-7858635-B2 | Spiro compounds as modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-12-28 | — | — | US | disclosed |
| US-20080015179-A1 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED | 2008-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242486-A1 | PYRIDINYL MORPHOLINE COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | HTR2C, HTR3D, HTR5A | POLB 4340/4885MEN1 753/4885CYP3A4 938/4885 |
| US-20110281862-A1 | ALFA-CARBOLINE INHIBITORS OF NPM-ALK, RET, AND BCR-ABL | ALK, BCR, NPM1 | POLB 2689/4885MEN1 1324/4885CYP3A4 3175/4885 |
| US-10550073-B2 | Benzamide derivative | CYP3A5, ABCB1, CYP2D6 | POLB 2174/4885MEN1 1387/4885CYP3A4 14/4885 |
| US-20080015179-A1 | Modulators of muscarinic receptors | CHRM3, CHRM5, CHRM2 | POLB 4473/4885MEN1 2672/4885CYP3A4 1260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.